FDA Reclassifies Proellex® Clinical Hold Status: Repros Therapeutics Inc. to Proceed With Phase 2 Study of Low Dose Oral Proellex® in the Treatment of Endometriosis

Published: Oct 08, 2012

THE WOODLANDS, Texas, Oct. 8, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the FDA has agreed to a reclassification of the full clinical hold on further oral Proellex® studies to a partial clinical hold to allow the Company to conduct a Phase 2 study of low dose oral Proellex® in the treatment of endometriosis. The Company believes the data generated from the study should allow the remaining partial clinical hold to be removed. The following points are the key elements of the 4 month trial:

Back to news